- Home
- YI vs ATNM Comparison
YI vs ATNM Comparison
Compare YI & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YI
- ATNM
- Stock Information
- Founded
- YI 2010
- ATNM 2000
- Country
- YI China
- ATNM United States
- Employees
- YI N/A
- ATNM N/A
- Industry
- YI Retail-Drug Stores and Proprietary Stores
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- YI Consumer Staples
- ATNM Health Care
- Exchange
- YI Nasdaq
- ATNM Nasdaq
- Market Cap
- YI 56.5M
- ATNM 40.6M
- IPO Year
- YI N/A
- ATNM N/A
- Fundamental
- Price
- YI $8.00
- ATNM $1.42
- Analyst Decision
- YI
- ATNM Strong Buy
- Analyst Count
- YI 0
- ATNM 4
- Target Price
- YI N/A
- ATNM $8.75
- AVG Volume (30 Days)
- YI 10.7K
- ATNM 354.3K
- Earning Date
- YI 05-22-2025
- ATNM 05-16-2025
- Dividend Yield
- YI N/A
- ATNM N/A
- EPS Growth
- YI N/A
- ATNM N/A
- EPS
- YI N/A
- ATNM N/A
- Revenue
- YI $1,973,017,082.00
- ATNM N/A
- Revenue This Year
- YI N/A
- ATNM N/A
- Revenue Next Year
- YI N/A
- ATNM N/A
- P/E Ratio
- YI N/A
- ATNM N/A
- Revenue Growth
- YI N/A
- ATNM N/A
- 52 Week Low
- YI $0.41
- ATNM $1.03
- 52 Week High
- YI $11.35
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- YI 49.29
- ATNM 55.96
- Support Level
- YI $7.48
- ATNM $1.35
- Resistance Level
- YI $8.40
- ATNM $1.64
- Average True Range (ATR)
- YI 0.36
- ATNM 0.14
- MACD
- YI -0.02
- ATNM 0.01
- Stochastic Oscillator
- YI 40.16
- ATNM 63.85
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.